Osteopontin expression of circulating T cells and plasma osteopontin levels are increased in relation to severity of heart failure

Circulation Journal

Volumn 71, Issue 12, 2007, Pages 1879-1884

  Soejima, Hirofumi ^a,b   Irie, Atsushi ^a   Fukunaga, Takashi ^a   Oe, Yoko ^a   Kojima, Sunao ^a   Kaikita, Koichi ^a   Kawano, Hiroaki ^a   Sugiyama, Seigo ^a   Yoshimura, Michihiro ^a   Kishikawa, Hideki ^b   Nishimura, Yasuharu ^a   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Heart failure; Inflammation; Leukocytes

Indexed keywords

OSTEOPONTIN;

AGED; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RATING SCALE; T LYMPHOCYTE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME;

EID: 37149054146     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1879     Document Type: Article

References (25)

1. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 1986; 83: 8819-8823.
2. Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, et al. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 1997; 96: 3063-3071.
3. Singh K, Sirokman G, Communal C, Robinson KG, Conrad CH, Brooks WW, et al. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension 1999; 33: 663-670.
4. Williams EB, Halpert L, Wickline S, Davison G, Parks W, Rottman J. Osteopontin expression is increased in the heritable cardiomyopathy of Syrian hamsters. Circulation 1995; 92: 705-709.
5. Arnlöv J, Evans JC, Benjamin EJ, Larson MG, Levy D, Sutherland P, et al. Clinical and echocardiography correlates of plasma osteopontin in the community: The Framingham Heart Study. Heart 2006; 92: 1514-1515.
6. + T cells in patients with unstable angina. Circ J 2006; 70: 851-856.
7. Suezawa C, Kusachi S, Murakami T, Toeda K, Hirohata S, Nakamura K, et al. Time-dependent changes in plasma osteopontin levels in patients with anterior-wall acute myocardial infarction after successful reperfusion: Correlation with left-ventricular volume and function. J Lab Clin Med 2005; 145: 33-40.
8. Tamura A, Shingai M, Aso N, Hazuku T, Nasu M. Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction. Circ J 2003; 67: 742-744.
9. O'Regan AW, Chupp GL, Lowly JA, Goetschkes M, Mulligan N, Berman JS. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol 1999; 162: 1024-1031.
10. Yamamoto S, Nasu K, Ishida T, Setoguchi M, Higuchi Y, Hijiya N, et al. Effect of recombinant osteopontinon adhesion and migration of 388D1 cells. Ann NY Acad Sci 1995; 760: 378-380.
11. Singh RP, Patarca R, Schwartz J, Cantor H. Definition of the specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and the murine macrophages in vitro and its effect upon macrophages in vivo. J Exp Med 1990; 171: 1931-1942.
12. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almedia M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998; 152: 353-358.
13. Yndestad A, Holm AM, Muller F, Simonsen S, Froland SS, Gullestad L, et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003; 60: 141-146.
14. Satoh S, Oyama JI, Suematsu N, Kadokami T, Shimoyama N, Okutsu M, et al. Increased productivity of tumor necrosis factor-alpha in helper T cells in patients with systolic heart failure. Int J Cardiol 2005; 11: 405-412.
15. Sahn DJ, Demaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
16. Schiller NB, Shah PM, Crawford M, Demaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367.
17. Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, et al. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 2000; 77: 487-498.
18. Devaux B, Scholz D, Hirche A, Klovekorn WP, Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997; 18: 470-479.
19. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87: 464-469.
20. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
21. Grantham JA, Burnett JC Jr. BJNP: Increasing importance in the pathophysiology and diagnosis of congestive heart failure. Circulation 1997; 96: 388-390.
22. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-1353.
23. Stawowy P, Blaschke F, Pfautsch P, Goetze S, Lippek F, Wollert-Wulf B, et al. Increased myocardial expression of osteopontin in patients with advanced heart failure. Eur J Heart Fail 2002; 4: 139-146.
24. Damas JK, Eiken HG, Oie E, Bjerkeli V, Yndestad A, Ueland T, et al. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 2000; 47: 778-787.
25. Varda-Bloom N, Leor J, Ohad DG, Hasin Y, Amar M, Fixler R, et al. Cytotoxic T lymphocytes are activated following myocardial infarction and can recognize and kill healthy myocytes in vitro. J Mol Cell Cardiol 2000; 32: 2141-2149.